Global survey of the immunomodulatory potential of common drugs-Reference-Cited by-同舟云学术

Global survey of the immunomodulatory potential of common drugs

Published:2017-04-24 Issue:6 Volume:13 Page:681-690
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Vladimer Gregory I^ORCID,Snijder Berend^ORCID,Krall Nikolaus^ORCID,Bigenzahn Johannes W^ORCID,Huber Kilian V M^ORCID,Lardeau Charles-Hugues,Sanjiv Kumar,Ringler Anna,Berglund Ulrika Warpman,Sabler Monika,de la Fuente Oscar Lopez,Knöbl Paul,Kubicek Stefan^ORCID,Helleday Thomas,Jäger Ulrich,Superti-Furga Giulio^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.2360.pdf

Reference56 articles.

1. Snijder, B. et al. Population context determines cell-to-cell variability in endocytosis and virus infection. Nature 461, 520–523 (2009).

2. Germain, R.N., Robey, E.A. & Cahalan, M.D. A decade of imaging cellular motility and interaction dynamics in the immune system. Science 336, 1676–1681 (2012).

3. Mahoney, K.M., Rennert, P.D. & Freeman, G.J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561–584 (2015).

4. Hoos, A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235–247 (2016).

5. Sharma, P. & Allison, J.P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction;Bioorganic & Medicinal Chemistry;2024-09

2. Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction;European Journal of Medicinal Chemistry;2024-09

3. Mapping the Human Cell Surface Interactome: A Key to Decode Cell-to-Cell Communication;Annual Review of Biomedical Data Science;2024-08-23

4. The cellular hierarchy of acute myeloid leukemia informs personalized treatment;2024-07-24

5. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial;JTO Clinical and Research Reports;2024-07